





First Quarter 2026 Performance Summary


May 2026


 **TOTAL REVENUE**
\$782 M -2% y/y¹


 **Tyvaso²**
\$458M -2% y/y

 **Remodulin**
\$127M -8% y/y


 **Orenitram**
\$136M +12% y/y

 **Unituxin**
\$54M -8% y/y


TTM OPERATING CASH FLOW
\$1.6 billion


CASH, CASH EQUIVALENTS, & MARKETABLE INVESTMENTS
\$3.5 billion

Quarterly Revenue, millions USD



Quarterly Highlights



- Most prescribed U.S. prostacyclin



- Most prescribed parenteral prostacyclin in the U.S.



- Seventeenth consecutive quarter of quarterly y/y revenue growth



- Most prescribed antibody therapy for high-risk neuroblastoma in the U.S.

1. y/y = year over year. 2. Tyvaso DPI + Nebulized Tyvaso. 3. CAGR = compound annual growth rate calculated from 1Q/21 to 1Q/26. 4. As of 12/31/2025.

NASDAQ

UTHR

2025 Financials

PRODUCT REVENUE

~\$3.2 billion

REVENUE/EMPLOYEE

~\$2.3 million

FOUNDED

1996

HQ

**Research Triangle Park, NC
Silver Spring, MD**

EMPLOYEES

>1,400⁴

Pipeline

Development Engine Addressing Unmet Needs

Non-Registration Registration Filed Approved

Drugs & Devices

TETON-1 - Nebulized Tyvaso® - Idiopathic Pulmonary Fibrosis - U.S. and Canada
TETON-2 - Nebulized Tyvaso® - Idiopathic Pulmonary Fibrosis - ROW ¹
TETON-PPF - Nebulized Tyvaso® - Progressive Pulmonary Fibrosis
SUMMIT - Pulmonary Hypertension Associated with COPD
Treprostinil Soft Mist Inhaler - PAH/PH-ILD/PH-COPD/IPF/PPF
Treprostinil-Iloprost - SMI PRN ¹⁰ - PAH
ADVANCE OUTCOMES - Ralinepag - PAH ²
Ralinepag DPI - PAH/PH-ILD/IPF/PPF
Ralinepag Triple Combination ⁹ - PAH

Xeno, Organs, and Organ Alternatives

EVL ³ /CLES ⁴ - Lung Transplant
EXPAND - UKidney™ - End Stage Renal Disease ⁵
EXTEND - UThymoKidney™ - End Stage Renal Disease ⁵
miroliverELAP ⁶ - Acute Liver Failure

Pre-clinical Xeno and Organ Alternative Programs

EXPRESS - UHeart™ - End Stage Heart Disease	ULung™ - End Stage Lung Disease	miroliver® - End Stage Liver Disease
ULobe™ - End Stage Lung Disease	IVIVA Kidney - End Stage Renal Disease	mirokidney® - End Stage Renal Disease

Pipeline Spotlights

TETON-1 Study Met Primary Endpoint	ADVANCE OUTCOMES Study Met Primary Endpoint	NEW DEVICES Treprostinil SMI and Ralinepag DPI
---	--	---

How We Operate

CURRENT COMMERCIAL PORTFOLIO	DRUG/ DEVICE PIPELINE	ORGAN PIPELINE
<p>Tyvaso DPI Nebulized Tyvaso Orenitram Remodulin Unituxin</p> <hr/> <p>PAH PH-ILD</p>	<p>Tyvaso DPI Treprostinil SMI⁷ Nebulized Tyvaso Ralinepag Ralinepag DPI Ralinepag Triple Combo Treprostinil-Iloprost SMI EVL³</p> <hr/> <p>PAH PH-ILD PH-COPD⁸ IPF PPF LUNG TRANSPLANT</p>	<p>Xenotransplantation Autologous Regenerative Medicine Allogeneic Regenerative Medicine</p> <hr/> <p>XENO AND ORGAN ALTERNATIVES</p>

This Fact Sheet contains forward-looking statements that are subject to risks and uncertainties, which are described in greater detail at ir.unither.com/disclaimer

1. ROW = rest of world outside the U.S. and Canada. 2. PAH = pulmonary arterial hypertension. 3. EVLP = ex-vivo lung perfusion. 4. CLES = centralized lung evaluation system. 5. Registrational status pending agreement with the FDA. 6. ELAP = external liver assist product. 7. SMI = soft mist inhaler. 8. PH-COPD = pulmonary hypertension associated with chronic obstructive pulmonary disease. 9. Triple combination consists of ralinepag + ERA + PDE5i 10. PRN = pro re nata ("as-needed")

Learn More



United Therapeutics' Corporate Website



United Therapeutics' Investor Relations Website



United Therapeutics' LinkedIn



United Therapeutics' Corporate Responsibility Website